Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Author(s):: Heijde, D. van der; Gladman, D.D.; Kishimoto, M.; Okada, M.; Rathmann, S.S.; Moriarty, S.R.; Shuler, C.L.; Carlier, H.; Benichou, O.; Mease, P.J.

Published: 2018
Publication type: Article / Letter to editor

BIOLOGIC DMARDPSORIATIC ARTHRITISSPONDYLOARTHRITISTREATMENT

Date issued: 2018-03-01
Language: English
Is part of: The Journal of Rheumatology (2018), Vol. 45, no. 3, p. 367-377
hdl: 1887/76947
doi: 10.3899/jrheum.170429
URL: http://www.jrheum.org/content/45/3/367